Pre-B acute lymphoblastic leukemia with b3a2 (p210) and e1a2 (p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2 (p210) clone

Leukemia

Volumn 13, Issue 12, 1999, Pages 2007-2011

  Winter, S S ^a   Greene, J M ^b   McConnell, T S ^b   Willman, C L ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; BCR ABL; Chronic myelogenous leukemia; p190; p210; Philadelphia chromosome

Indexed keywords

BCR ABL PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; MESSENGER RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER RECURRENCE; CASE REPORT; CELL CLONE; CELL DIFFERENTIATION; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; HUMAN; IMMUNOGLOBULIN GENE; MALE; PRIORITY JOURNAL; SOUTHERN BLOTTING;

EID: 0032715894     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401598     Document Type: Article

References (30)

1. Riheiro RC, Abromowitch M, Raimondi SC, Murphy SB, Behm F, Williams DL. Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood 1987; 70: 948-953.
2. Seeker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, bcr breakpoint and prognostic significance. Leukemia 1991; 5: 196-199.
3. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375-2384.
4. Pane F, Frigeri F, Sindona M, Cuciano L, Ferrara F, Cimino R, Meloni G, Stiglio G, Salvatore F, Rotoli B. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABI with c3/a2 junction). Blood 1996; 88: 2410-2414.
5. Hochas A, Reiter A, Skladny H, Melo JV, Sick C, Berger U, Guo JQ, Arlinghaus RB, Hehlman R, Goldman JM, Cross NCP. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 1996; 88: 2236-2240.
6. Iwata S, Mizutani S, Nakazawa S, Yata J. Heterogeneity of the breakpoint in the ABL gene in cases with BCR/ABL transcript lacking ABL exon a2. Leukemia 1994; 8: 1696-1702.
7. Suryanarayan K, Hunger SP, Kohler S, Carroll AJ, Crist W, Link MP, Cleary ML. Consistent involvement of the bcr gene by 9;22 breakpoints in pediatric acute leukemias. Blood 1991: 77: 324-330.
8. Lugo TG, Pendergast A-M, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 24: 1079-1081.
9. Goga A, McLaughlin J, Afar DEH, Saffran D, Witte ON. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 1995; 82: 981-988.
10. Voncken JW, Kaartinen V, Pattengale PK, Germeraad TV, Groffen I, Heisterkamp N. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood 199; 86: 4601-4611.
11. Castellanos A, Pintado B, Weruagua E, Arevalo R, Lopez A, Orfoa A. Sanchez-Garcia I. A RCR-ABL p190 fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence ot the endogenous bcr product. Blood 1997; 90: 2168-2174.
12. Kurzrock R, Shtalrid M, Talpaz M, Kloetzer WS, Gutterman JU. Expression of c-abl in Philadelphia-positive acute myelogenous leukemia. Blood 1987; 70: 1584-1388.
13. Tuszynski A, Dhut S, Young BD, Lister TA, Rohatiner AZ, Amess IAL, Chaplin T, Dorey E, Gibbons B. Detection and significance of bcr-abl mRNA transcripts and fusion proteins in Philadelphia-positive adult acute lymphoblastic leukemia. Leukemia 1993; 7: 1504-1508.
14. Anderson JR, Wilson JF, Jenkin DT, Meadows AT, Kersey J, Chilcote RR, Coccia P, Exelby P, Kushner J, Siegel S, Hammond D. Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). New Engl J Med 1983; 308: 559-565.
15. Foucar K, Chen IM, Crago S. Organization and operation of a flow cytometric immunophenotyping laboratory. Semin Diag Path 1989; 6: 13-36.
16. Willman CL, Stewart CC. General principles of multiparameter flow cytometric analysis. Semin Diag Path 1989; 6: 3-12.
17. Saikevych IA, Kerrigan DP, McConnell TS, Head DR, Appelbaum FR, Willman CL. Multiparameter analysis of acute mixed lineage leukemia: correlation of a B/myeloid immunophenotype and immunoglobulin and T cell receptor gene rearrangements with the presence of the Philadelphia chromosome translocation in acute leukomias with myeloid morphology. Leukemia 1991; 5: 373-382.
18. Willman CL, Griffith BB, Whittaker M. Molecular genetic approaches for the diagnosis of clonality in lymphoid neoplasms. Clin Lab Med 1990; 10: 119-149.
19. Schaefer-Rego K, Dudek H, Popenoe D, Arlin Z, Mears JG, Bank A, Leibowitz D. CML patients in blast crisis have breakpoints localized to a specific region of the BCR. Blood 1987; 70: 448-455.
20. Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON, McCormick FP. Diagnosis of chronic myeloid and acute lymphocylic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci USA 1988; 85: 5698-5702.
21. Mitelman F (ed). Guidelines for Cancer Cytogenetics: Supplement to an International System for Human Cytogenetic Nomenclature. Karger: Basel, 1991.
22. Dhingra K, Talpaz M, Katarjian H, Ku S, Rothberg J, Gutterman JU, Kurzrock R. Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression. Leukemia 1991; 5: 191-195.
23. Fujie H, Tsuchiya S, Morita S, Itano M, Yambe T, Ohasi Y, Minegishi N, Minegishi M, Satou T, Konno T. bcr/abl mRNA in leukemic blasts of an unusual patient with acute lymphoblastic leukemia followed after 5-year remission by chronic myelogenous leukemia in blast crisis. Leukemia 1994; 8: 1592-1595.
24. Saglio G, Fabrizio P, Gottardi E, Frigeri F, Buonaiuto MA, Guerrasio A, De Micheli D, Parziale A, Fornaci MN, Martinelli G, Salvatore F. Consistent amounts of acute leukemia-associated p190BCR-ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. Blood 1996; 87: 1075-1080.
25. Kelliher M, Knott A, McLaughlin J, Witte ON, Rosenberg N. Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene. Mol Cell Biol 1991; 11: 4710-4716.
26. Hermans A, Heisterkamp, von Lindern M, van Baal S, Meijer D, van der Plas D, Wiedemann LM, Grotten J, Bootsma D, Grosveld G. Unique fusion of of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 1987; 51: 33-40.
27. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC transformation by ABL oncogenes. Cell 1992; 70: 901-910.
28. Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey IH, Johnstone HS, Sather H, Trigg ME. Chappell R, Hammond D, Bleyer WA. Cytoreduction and prognosis in acute lymphoblastic leukemia - the importance ot early marrow response: report from the Children's Cancer Group. J Clin Oncol 1996; 14: 389-398.
29. Sierra J, Radich J, Hansen JA, Martin PJ, Petersdorf EW. Bjerk J, Bryant E, Nash RA, Saucers IE, Storb R, Sullivan KM, Appelbaum FR, Anasetti C. Marrow transplants from unrelated donors for treatment of Philadelphia-chromosome positive acute lymphoblastic leukemia. Blood 1997; 90: 1410-1414.
30. Enright H, McGlave PB. Biology and treatment of chronic myelogenous leukemia. Ontology 1997; 11: 1295-1300.